European S3-guidelines on the systemic treatment of psoriasis vulgaris.
نویسندگان
چکیده
Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.
منابع مشابه
Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC.
متن کامل
[Commentary on European and British guidelines for the treatment of psoriasis].
The European S3 guidelines on the systemic treatment of psoriasis1 and the British Association of Dermatologists’ guidelines for biologic interventions for psoriasis2 were published shortly after the Spanish guidelines, whose coauthors included the authors of this article.3 Without entering into an exhaustive discussion of the transcription or even conceptual errors that may be found in any pub...
متن کاملFumaric acid esters in the management of psoriasis
Fumaric acid esters (FAE) are small molecules with immunomodulating, anti-inflammatory, and anti-oxidative effects. FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands. The development of FAE as psoriasis treatment did not follow the traditional drug development phases. Nonetheless, in...
متن کاملSwiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of lif...
متن کاملTreatment of severe psoriasis with fumaric acid esters: scienti®c background and guidelines for therapeutic use U.MROWIETZ, E.CHRISTOPHERS AND P.ALTMEYER* FOR THE GERMAN FUMARIC ACID ESTER CONSENSUS CONFERENCE
Fumaric acid ester (FAE) therapy has proved to be safe and effective in patients with severe psoriasis vulgaris. This treatment was introduced nearly 30 years ago, but is only now gaining renewed interest among dermatologists. FAE therapy is licensed in Germany and registration is pending in many European countries. Multicentre trials have con®rmed the bene®cial effect of FAE in psoriasis and h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the European Academy of Dermatology and Venereology : JEADV
دوره 23 Suppl 2 شماره
صفحات -
تاریخ انتشار 2009